Genomic Health, Inc.
(NASDAQ GS: GHDX)
Attention investors who purchased shares of Genomic Health, Inc. before July 29, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of Genomic Health, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Exact Sciences Corporation.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Genomic Health, Inc. (“Genomic Health” or the “Company”) (NASDAQ GS: GHDX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Exact Sciences Corporation (“Exact Sciences”) (NASDAQ CM: EXAS) in a transaction valued at approximately $2.8 billion. Under the terms of the agreement, shareholders of Genomic Health will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock. Upon closing, Exact Sciences shareholders are expected to own approximately 91% of the combined company, and Genomic Health stockholders are expected to own approximately 9%.
If you own common stock of Genomic Health and purchased any shares before July 29, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at email@example.com, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.